石药集团(01093)：罗沙司他胶囊获药品注册批件

智通财经07-05

智通财经APP讯，石药集团(01093)发布公告，集团开发的罗沙司他胶囊(20mg/50mg)(该产品)已获得中华人民共和国国家药品监督管理局颁发的药品注册批件。该产品为中国首仿获批，并视同通过仿制药质量和疗效一致性评价。据悉，罗沙司他是全球第一个低氧诱导因子–脯氨酰羟化酶抑制剂(HIF-PHI)，适用于正在接受透析及非透析治疗的患者因慢性肾脏病(CKD)所引起的贫血。罗沙司他作为新一代机制全新的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2449517342?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-05 17:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2449517342","market":"hk","top_or_hot":-1,"title":"石药集团(01093)：罗沙司他胶囊获药品注册批件","media":"智通财经","content":"<div>\n<p>智通财经APP讯，石药集团(01093)发布公告，集团开发的罗沙司他胶囊(20mg/50mg)(该产品)已获得中华人民共和国国家药品监督管理局颁发的药品注册批件。该产品为中国首仿获批，并视同通过仿制药质量和疗效一致性评价。据悉，罗沙司他是全球第一个低氧诱导因子–脯氨酰羟化酶抑制剂(HIF-PHI)，适用于正在接受透析及非透析治疗的患者因慢性肾脏病(CKD)所引起的贫血。罗沙司他作为新一代机制全新的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1146211.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药集团(01093)：罗沙司他胶囊获药品注册批件</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药集团(01093)：罗沙司他胶囊获药品注册批件\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-05 17:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1146211.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，石药集团(01093)发布公告，集团开发的罗沙司他胶囊(20mg/50mg)(该产品)已获得中华人民共和国国家药品监督管理局颁发的药品注册批件。该产品为中国首仿获批，并视同通过仿制药质量和疗效一致性评价。据悉，罗沙司他是全球第一个低氧诱导因子–脯氨酰羟化酶抑制剂(HIF-PHI)，适用于正在接受透析及非透析治疗的患者因慢性肾脏病(CKD)所引起的贫血。罗沙司他作为新一代机制全新的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1146211.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0326950275.SGD","symbol_name":"Schroder ISF China Opportunities A Acc SGD-H","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1146211.html","article_id":"2449517342","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2449517342","pubTimestamp":1720172155,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，石药集团 发布公告，集团开发的罗沙司他胶囊(该产品)已获得中华人民共和国国家药品监督管理局颁发的药品注册批件。该产品为中国首仿获批，并视同通过仿制药质量和疗效一致性评价。在《中国肾性贫血诊治临床实践指南》及《罗沙司他治疗肾性贫血中国专家共识》中，罗沙司他获最高级别(1A级)推荐。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","01093":"石药集团","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","IE0008368742.USD":"首域中国增长基金I Acc","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","BK1521":"挪威政府全球养老基金持仓","BK1515":"抗疫概念","BK1191":"制药"},"translate_title":"CSPC Pharmaceutical Group (01093): Roxastat Capsules Obtained Drug Registration Approval","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"智通财经APP讯，石药集团(01093)发布公告，集团开发的罗沙司他胶囊(20mg/50mg)(该产品)已获得中华人民共和国国家药品监督管理局颁发的药品注册批件。该产品为中国首仿获批，并视同通过仿制药质量和疗效一致性评价。据悉，罗沙司他是全球第一个低氧诱导因子–脯氨酰羟化酶抑制剂(HIF-PHI)，适用于正在接受透析及非透析治疗的患者因慢性肾脏病(CKD)所引起的贫血。罗沙司他作为新一代机制全新的口服肾性贫血治疗药物，通过激活HIF通路，促进内源性促红细胞生成素(EPO)生成，下调铁调素水平，改善铁的吸收、转运和利用，纠正贫血。在《中国肾性贫血诊治临床实践指南》及《罗沙司他治疗肾性贫血中国专家共识》中，罗沙司他获最高级别(1A级)推荐。该产品的获批将进一步丰富集团在血液和造血系统治疗领域的产品线，并为患者提供新的选择。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2449517342"}